Pyridostigmine
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Pyridostigmine: Autoimmune disease of peripheral nervous system
One-Sentence Summary
Pyridostigmine is a reversible acetylcholinesterase inhibitor, originally used for symptomatic treatment of myasthenia gravis and other neuromuscular junction disorders. There are currently no registered clinical trials and 3 publications (none testing pyridostigmine in this subgroup) supporting this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Autoimmune disease of peripheral nervous system |
| TxGNN Prediction Score | 0.9975 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Pyridostigmine is known to be a reversible acetylcholinesterase inhibitor. It increases acetylcholine at the neuromuscular junction, which is the basis of its standard use as symptomatic therapy for acetylcholine receptor antibody-positive myasthenia gravis.
Thymic hyperplasia is a common pathological feature of that disease, so the predicted indication largely overlaps with the original one. The mechanism applies directly: any form of myasthenia gravis with impaired neuromuscular transmission may benefit from symptomatic cholinesterase inhibition.
The supporting literature does not test pyridostigmine in this subgroup. It consists of a genomic/epigenetic review, a case report on MuSK-positive disease, and a retrospective study of thymectomy outcomes.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25683765 | 2015 | Cohort | Journal of Neurology | Two-year outcomes of thymectomy in 39 patients with non-thymomatous, late-onset, AChR antibody-positive generalised MG; no pyridostigmine data |
| 34225443 | 2021 | Review | Molecular Medicine Reports | Genomic, phenotypic and epigenetic insights into MG pathology and autoimmunity |
| 18053719 | 2008 | Case report | Neuromuscular Disorders | Dropped head syndrome in a MuSK-positive MG patient with thymic hyperplasia |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 14392L | Mestinon | Tablet containing pyridostigmine bromide 10 mg | Not stated in the data compiled for this report |
Safety Considerations
- Conditions flagged as contraindications in the knowledge graph (not label text): kidney disease, pyoureter, asthma (including intrinsic and allergic asthma), and urinary tract obstruction.
- Drug Interactions: 78 interactions were identified, and the 20 listed in the data are all rated Moderate. They include:
- Corticosteroids: hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, budesonide, triamcinolone
- Anticholinergics/antimuscarinics: atropine, scopolamine, hyoscyamine, glycopyrronium, methscopolamine, propantheline, trospium, dicyclomine, clidinium, mepenzolate
- Aminoglycosides: neomycin, kanamycin, paromomycin
Product Information warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is essentially a subtype of an established use, so it offers little true repurposing value. There are no trials, and the literature does not test pyridostigmine in this subgroup. Evidence is limited to model prediction and general background literature (L4).
To proceed, the following is needed:
- The TGA-approved PI, including approved indications, warnings and contraindications
- Detailed mechanism of action data
- Subgroup data on pyridostigmine response in thymic hyperplasia-associated MG (for example, from existing MG cohorts)
- Review of the knowledge-graph contraindication flags (asthma, urinary obstruction, kidney disease) against the PI
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.